New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study

Zhou Jie; Xu Yixin; Wang Haitao; Liu Zhilin

doi:10.1515/med-2024-0994

Open Medicine (Jul 2024)

New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study

Zhou Jie,
Xu Yixin,
Wang Haitao,
Liu Zhilin

Affiliations

Zhou Jie: Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu Province, 213003, China
Xu Yixin: Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University, No. 2, Yongning North Road, Changzhou, Jiangsu Province, 213003, China
Wang Haitao: Department of General Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China
Liu Zhilin: Department of General Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China

DOI: https://doi.org/10.1515/med-2024-0994
Journal volume & issue: Vol. 19, no. 1
pp. 2547 – 59

Abstract

Read online

No intervention definitively extends transplant-free survival in primary sclerosing cholangitis (PSC). Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), may enhance PSC prognosis, but their efficacy is debated.

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal

Abstract

Keywords